Aurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
